TRX-100 SAD and Food Effect Study in Healthy Volunteers

Phase 1, randomised, double-blind trial of tivoxavir marboxil in influenza (4 cohorts), sponsored by Traws Pharma, Inc. Primary endpoints: Incidence, severity, and relationship of treatment-emergent adverse events at Day 28 and Incidence of serious adverse events and adverse events leading to discontinuation at Day 28. Started Mar 2026; status: recruiting.